Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
2 May 24
8-K
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
2 May 24
ARS
2023 FY
Annual report to shareholders
5 Apr 24
DEFA14A
Additional proxy soliciting materials
5 Apr 24
DEF 14A
Definitive proxy
5 Apr 24
8-K
Entry into a Material Definitive Agreement
27 Feb 24
424B5
Prospectus supplement for primary offering
27 Feb 24
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
27 Feb 24
8-K
Departure of Directors or Certain Officers
2 Feb 24
8-K
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
6 Dec 23
424B5
Prospectus supplement for primary offering
6 Dec 23
424B5
Prospectus supplement for primary offering
4 Dec 23
8-K
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
28 Nov 23
8-K
SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN
17 Nov 23
UPLOAD
Letter from SEC
14 Nov 23
CORRESP
Correspondence with SEC
8 Nov 23
S-3ASR
Automatic shelf registration
2 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
2 Nov 23
UPLOAD
Letter from SEC
13 Oct 23
8-K
Departure of Directors or Certain Officers
1 Sep 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
8-K
SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
2 Aug 23
8-K
SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA
5 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
25 May 23
8-K
SpringWorks Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
3 May 23
10-Q
2023 Q1
Quarterly report
3 May 23
ARS
2022 FY
Annual report to shareholders
7 Apr 23
DEFA14A
Additional proxy soliciting materials
7 Apr 23
DEF 14A
Definitive proxy
7 Apr 23
8-K
Regulation FD Disclosure
10 Mar 23
S-8
Registration of securities for employees
28 Feb 23
10-K
2022 FY
Annual report
28 Feb 23
8-K
SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights
28 Feb 23
8-K
SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
3 Nov 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
424B3
Prospectus supplement
26 Sep 22
8-K
Departure of Directors or Certain Officers
16 Sep 22
Latest ownership filings
4
Bhavesh Ashar
3 Apr 24
144
Notice of proposed sale of securities
1 Mar 24
4
Daniel Pichl
20 Feb 24
144
Notice of proposed sale of securities
16 Feb 24
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Bhavesh Ashar
5 Feb 24
4
Daniel Pichl
5 Feb 24
144
Notice of proposed sale of securities
2 Feb 24
144
Notice of proposed sale of securities
2 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24
SC 13G/A
STATE STREET CORP
23 Jan 24
4
Herschel S Weinstein
8 Jan 24
4
L. Mary Smith
8 Jan 24
4
Saqib Islam
8 Jan 24
4
Daniel Pichl
8 Jan 24
4
Francis I Perier Jr
8 Jan 24
4
Michael Nofi
8 Jan 24
4
Tai-An Lin
8 Jan 24
4
Badreddin Edris
8 Jan 24
4
James Cassidy
8 Jan 24
4
Bhavesh Ashar
8 Jan 24
SC 13D/A
ORBIMED ADVISORS LLC
6 Dec 23
4
Saqib Islam
1 Dec 23
144
Notice of proposed sale of securities
2 Nov 23
4
Tai-An Lin
4 Oct 23
3
Tai-An Lin
15 Sep 23
4
James Cassidy
8 Sep 23
4
Julie Hambleton
21 Jul 23
4
James Cassidy
5 Jul 23
4
L. Mary Smith
5 Jul 23
4
Julie Hambleton
22 Jun 23
144
Notice of proposed sale of securities
20 Jun 23
4
Jeffrey Lawrence Schwartz
25 May 23
4
DANIEL LYNCH
25 May 23
4
Freda C Lewis-Hall
25 May 23
4
Julie Hambleton
25 May 23
4
Alan Fuhrman
25 May 23